Most solid tumors are insensitive to single-agent immunotherapy, calling for the development of combinatorial treatment regimens. Recently, Lin and collaborators developed a pharmacological platform enabling the combination of different immunotherapies into a single chemical entity. This approach may effectively circumvent obstacles associated with the simultaneous delivery of multiple immunotherapeutic agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.tips.2024.12.001 | DOI Listing |
Publication Analysis
Top Keywords
novel pharmacological
4
pharmacological entity
4
entity integrated
4
integrated multimodal
4
multimodal immunotherapy
4
immunotherapy solid
4
solid tumors
4
tumors insensitive
4
insensitive single-agent
4
single-agent immunotherapy
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!